Free tool
FAERS Monitor: Vizimpro
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 211288 or its brand name (Vizimpro, Dacomitinib). Reports on generic versions are filed under their own applications.
Reports
749
Serious
692
92% of reports
Hospitalization
215
Death reported
330
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death238
- diarrhoea121
- rash115
- neoplasm progression78
- paronychia58
- blood pressure increased47
- malignant neoplasm progression45
- pruritus36
- off label use34
- dyspnoea32
- decreased appetite29
- vomiting28
- pain27
- carcinoembryonic antigen increased26
- drug interaction26
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2012 | 11 |
| 2013 | 14 |
| 2014 | 8 |
| 2015 | 3 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 5 |
| 2019 | 50 |
| 2020 | 77 |
| 2021 | 131 |
| 2022 | 207 |
| 2023 | 128 |
| 2024 | 55 |
| 2025 | 41 |
| 2026 | 16 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,410 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| carcinoembryonic antigen increasedSignal | 26 | 382.0 | 261.2 | 9,377 |
| paronychiaSignal | 58 | 375.6 | 292.8 | 21,017 |
| neoplasm progressionSignal | 78 | 63.1 | 51.2 | 4,706 |
| malignant neoplasm progressionSignal | 45 | 12.3 | 9.3 | 460 |
| blood pressure increasedSignal | 47 | 8.6 | 6.5 | 312 |
| deathSignal | 238 | 7.8 | 7.0 | 1,454 |
| rashSignal | 115 | 7.4 | 6.3 | 644 |
| diarrhoeaSignal | 121 | 5.3 | 4.5 | 427 |
| drug interactionSignal | 26 | 4.6 | 3.2 | 70 |
| decreased appetiteSignal | 29 | 3.5 | 2.5 | 50 |
| pruritusSignal | 36 | 2.6 | 1.9 | 35 |
| vomiting | 28 | 1.7 | 1.2 | 7 |
| dyspnoea | 32 | 1.6 | 1.1 | 7 |
| pain | 27 | 1.2 | 0.9 | 1 |
| off label use | 34 | 1.1 | 0.8 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.